Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients

スポンサーリンク

概要

• 論文の詳細を見る

• Teneligliptin is a novel peptidomimetic-chemotype prolylthiazolidine-based inhibitor of dipeptidyl peptidase-4 (DPP-4). The aim of this study was to evaluate the effects of teneligliptin on 24 h blood glucose control and gastrointestinal hormone responses to a meal tolerance test, and to investigate the glucose-lowering mechanisms of teneligliptin. Ten patients with type 2 diabetes mellitus (T2DM) were treated for 3 days with teneligliptin (20 mg/day). Postprandial profiles for glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, des-acyl ghrelin, and 24 h glycemic fluctuations were measured via continuous glucose monitoring for 4 days. Once daily teneligliptin administration for 3 days significantly lowered postprandial and fasting glucose levels. Significant elevations of fasting and postprandial active GLP-1 and postprandial active GIP levels were observed. Teneligliptin lowered postprandial glucose elevations, 24 h mean blood glucose levels, standard deviation of 24 h glucose levels and mean amplitude of glycemic excursions (MAGE) without hypoglycemia. Serum insulin levels in the fasting state and 30 min after a meal were similar before and after teneligliptin treatment; however significant reductions at 60 to 180 min after treatment were observed. A significant elevation in early-phase insulin secretion estimated by insulinogenic and oral disposition indices, and a significant reduction in postprandial glucagon AUC were observed. Both plasma ghrelin and des-acyl ghrelin levels were unaltered following teneligliptin treatment. Teneligliptin improved 24 h blood glucose levels by increasing active incretin levels and early-phase insulin secretion, reducing the postprandial insulin requirement, and reducing glucagon secretion. Even short-term teneligliptin treatment may offer benefits for patients with T2DM.

• 一般社団法人 日本内分泌学会の論文

著者

• Nakazato Masamitsu

  Division Of Neurology Respirology Endocrinology And Metabolism Department Of Internal Medicine Miyaz

• Ueno Hiroaki

  Division Of Neurology Respirology Endocrinology And Metabolism Department Of Internal Medicine Miyaz

• Tsuchimochi Wakaba

  Division Of Neurology Respirology Endocrinology And Metabolism Department Of Internal Medicine Miyaz

• NAKAMURA Shuji

  Heiwadai Memorial Hospital

• Nakazato Masamitsu

  Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

• Yamashita Eiichiro

  Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

• Tsubouchi Chikako

  Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

• Sakoda Hideyuki

  Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

関連論文

• Plasma Ghrelin Concentrations in Different Clinical Stages of Diabetic Complications and Glycemic Control in Japanese Diabetics
• A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets
• Significant lowering of plasma ghrelin but not des-acyl ghrelin in response to acute exercise in men
• Effects of Valsartan on Fibrinolysis in Hypertensive Patients With Metabolic Syndrome : The KACT-MetS Study
• Brachial Plexus Neurolymphomatosis:A Discrepancy between Electrophysiological and Radiological Findings
• Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients

スポンサーリンク